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speaker, Janet Segall, was recognized 
for her devoted and successful work as 
the first secretary of the International 
Pemphigus and Pemphigoid Foundation.
plenary sessions
The keynote lectures on stem cell behav-
ior (Dennis Roop, University of Colorado, 
Denver: “State of the Art on Epidermal 
Stem Cells”; Mayumi Ito, New York 
University, NY: “Stem Cells and Wound 
Healing”; Freddy Radtke, EPFL, Lausanne, 
Switzerland: “Notch Signaling in 
Epidermal Renewal and Disease”), migra-
tion (Zena Werb, University of California, 
San Francisco: “State of the Art on 
Epithelial Adhesion and Migration”), and 
adhesion-mediated signaling (Kathleen J. 
Green, Northwestern University, Chicago, 
IL: “Perspective on Desmosomes”) set 
the stage for a new paradigm in pem-
phigus research: the understanding that 
pemphigus antibodies act as triggers 
of outside-in signaling in keratinocytes 
whereas desmoglein cadherins serve 
as adhesion receptors and signal trans-
mitters. However, as demonstrated by 
several groups after passive transfer of 
antibodies into neonatal mice, the hope 
that inhibition of epidermal signaling 
molecules may allow new therapeutic 
approaches has not yet lived up to 
expectations. Many potential signaling 
targets are key regulators of epidermal 
homeostasis, and their long-term inhibi-
tion can be detrimental. Hence, further 
effort is required to refine therapies that 
The International Pemphigus Meeting* 
held in Berne, Switzerland, in June 2009, 
was designed as a forum in which to dis-
cuss cell signaling and signaling-related 
therapies in pemphigus disease. Under 
the theme “From Cell Signaling to Novel 
Therapeutic Concepts,” researchers and 
clinicians met with leaders in epidermal 
stem cell biology, adhesion, signal trans-
duction, migration, and autoimmunity 
(Figure 1). Keynote lectures on basic top-
ics were linked to specialized sessions 
on pemphigus, such as cell signaling and 
mechanisms of acantholysis, alterna-
tive aspects of immune responses, and 
unconventional treatments. Workshops 
and interactive poster sessions termi-
nated the day’s program; the latter gave 
young investigators the opportunity to 
present their research.
Two innovative studies were hon-
ored with the Young Investigator Award 
sponsored by the European Academy 
of Dermatology and Venereology: Cory 
Simpson from the Department of Pathology 
at Northwestern University, in Chicago, 
for his contribution to the study on modu-
lation of epidermal growth factor recep-
tor signaling by desmoglein 1 (Getsios et 
al., 2009), and Volker Spindler from the 
Department of Anatomy and Cell Biology, 
University of Würzburg, Germany, for 
investigations of desmocollin 3–mediated 
cell adhesion in pemphigus.
The congress also served as a platform 
for a subsidiary meeting on therapy, 
headed by Victoria Werth. The guest 
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control pemphigus at the level of kerati-
nocytes. New insights into the specific 
mode of action of pathogenic antibodies, 
through their cloning by phage display 
(Don Siegel and John Stanley, both from 
the University of Pennsylvania School of 
Medicine, Philadelphia: “State of the Art 
on Antibody-Mediated Immunity” and 
“Using Pemphigus Antibodies for Targeted 
Drug Delivery,” respectively), might serve 
this purpose. Moreover, these antigen-
restricted antibodies may be employed as 
vectors to specifically deliver drugs to the 
skin and its appendages. At the immune-
system level, novel immunosuppressive 
compounds—notably rituximab (anti-
CD20 antibody; Joly et al., 2007)—are ris-
ing as highly promising drugs to efficiently 
control the disease.
The meeting concluded with a short 
statement from two experts in the field. 
Both Masayuki Amagai (University 
of Tokyo, Keio University School of 
Medicine, Japan) and Grant Anhalt (John 
Hopkins University, Baltimore, MD) stat-
ed that, despite considerable progress in 
understanding the pathogenesis of pem-
phigus, major effort is now required to 
move toward specific treatment regimens.
Below, Spiro Getsios and Jens 
Waschke summarize discussions they 
chaired in Workshop I, on cell signaling. 
Luca Borradorri and Michael Hertl, who 
chaired Workshop II, on treatment, sum-
marize the discussion on scoring systems 
and conventional as well as novel 
therapeutic approaches.
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Workshop i: 
“the signaling network in pemphigus 
pathogenesis and potential therapeutic 
application” (Chairs: spiro getsios of 
northwestern University, Chicago, il, 
and Jens Waschke of the University of 
Würzburg, germany)
The textbook explanation for the 
pathophysiology of pemphigus is rela-
tively simple: autoantibodies sterically 
hinder desmoglein 3 and/or desmoglein 
1 to cause acantholysis in areas where 
these adhesion proteins are most abun-
dant. However, an increasing body of 
evidence suggests that desmogleins are 
also targeted outside of desmosomes 
and that a variety of intracellular signal-
ing pathways are involved in the loss of 
adhesion. The goal of the workshop was 
to examine the relationship between 
keratinocyte adhesion and signaling 
pathways and to evaluate critically the 
contribution of adhesion-signaling net-
works to pemphigus pathogenesis. The 
concept that pemphigus involves more 
than steric hindrance of adhesion pro-
teins by auto-antibodies emerged from 
the animated sessions; the complexity 
of pemphigus-associated adhesion and 
signaling events presents challenges for 
future investigation while at the same 
time affording opportunities for novel 
therapeutic intervention.
The workshop began by revisit-
ing ultrastructural findings in patients 
and animal models of pemphigus, 
which reveal two seemingly conflict-
ing pictures: (i) split desmosomes and 
frank acantholysis (loss of cell–cell 
contact) and (ii) intact desmosomes 
with intervening spongiosis (widening 
of intercellular spaces between 
desmosomes). These snapshots may 
reflect different moments in the spec-
trum of a dynamic blistering disease but 
also provide insight into different mod-
els of pemphigus pathogenesis. In par-
ticular, split desmosomes are consistent 
with the steric hindrance model, where-
as the observation of intact desmosomes 
with widened intercellular spaces lends 
itself to alternative pathomechanisms, 
such as impaired desmoglein trafficking, 
activation of desmoglein-dependent or 
-independent signaling pathways, and/
or molecular targets outside of the des-
mosomes. The discussants agreed that 
these explanations are not necessarily 
mutually exclusive and that more studies 
are required to identify which of these 
events are primary to the disease.
Although antidesmoglein antibodies 
are present in the majority of patients 
with pemphigus, and a monoclonal 
antibody (i.e., AK23) that interferes with 
the putative desmoglein 3 adhesive 
interface is sufficient to induce epider-
mal blistering, nonjunctional pools of 
desmogleins as well as other proteins 
appear also to be important pathogenic 
targets. Enhanced internalization of 
desmogleins and their trafficking into 
and out of desmosomes was consid-
ered a means of disrupting keratinocyte 
adhesion by specifically depleting des-
moglein 3 from desmosomes, without 
changes in other junctional proteins. 
It was noted, however, that the skin 
in mucosal-type pemphigus vulgaris, 
which contains considerable amounts 
of anti–desmoglein 3 anti bodies, would 
also be expected to blister if these anti-
bodies were simply shifting the balance 
of desmoglein assembly and disassem-
bly. The presence of other desmosomal 
cadherins (i.e., desmoglein 1) or the dif-
ferentiated state of keratinocytes might 
therefore influence susceptibility to 
anti–desmoglein 3 antibodies. The group 
emphasized that the choice of cell culture 
or animal model systems will impact the 
steady-state dynamics of the keratinocyte 
adhesive apparatus and should be taken 
into consideration when interpreting 
the effects of anti desmoglein antibod-
ies on trafficking events. The merits and 
limitations of various model systems and 
experimental tools were tabled for future 
discussion.
Additional mechanisms by which 
desmosomal adhesion is destabilized 
beyond steric hindrance were debated, 
including the extent to which proteolysis 
contributes to pemphigus. It was empha-
sized that proteases, such as matrix 
metalloproteinases and caspases, have 
multiple cellular targets that extend well 
beyond desmogleins and that this fact 
should be considered when accounting 
for the apparent specificity of desmog-
lein disruption in pemphigus.
The group also examined the potential 
contribution of nondesmoglein targets 
such as the desmocollins. Desmocollin 3 
collaborates with desmogleins to form the 
adhesive core of desmosomes and might 
serve as a bona fide target in pemphigus. 
Moreover, its genetic ablation leads to 
more severe blistering than the related 
desmoglein 3. Interestingly, homozygous 
null desmocollin 3 embryos die prior to 
implantation or desmosome formation, 
implicating signaling mechanisms in the 
normal function of this protein.
Day 2 focused on signaling events 
in pemphigus. Emerging data from sev-
eral groups suggest that desmogleins are 
both adhesion and signaling proteins. 
Widening of intercellular spaces and 
loss of desmosomes were considered as 
Figure 1. organizing committee (first row from left): Luca Borradori, Maja Suter, Eliane Müller, all 
University of Bern, Switzerland; John Stanley, University of Pennsylvania, Philadelphia USA (missing: 
Thomas Hunziker, University of Bern, Switzerland)
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different stages of a continuous process 
finally leading to acantholysis. The group 
evaluated whether widening of inter-
cellular spaces prior to the loss of des-
mosomes suggested that nonjunctional 
desmogleins or nondesmoglein antigens 
might be the initial targets of pathogenic 
antibodies. Indeed, most anti–desmog-
lein 3–specific antibodies appear to bind 
to Triton-soluble pools of desmoglein 
3, indicating that adhesive defects may 
originate outside of desmosomes. On the 
other hand, ultrastructural observations 
from lethal acantholytic epidermolysis 
bullosa suggest that there is more to the 
story. Here, mutations in desmoplakin—
the plaque protein required for keratin 
filament anchorage in desmosomes—
also lead to acantholysis, suggesting that 
the desmosome itself is ultimately the 
target of disease. Given that desmogleins 
are found outside desmosomes, widened 
interdesmosomal spaces themselves do 
not rule out desmogleins as primary tar-
gets in autoantibody binding.
The group considered the plethora 
of signaling events linked to pemphi-
gus and the question of what accounts 
for the specificity of signaling path-
ways to desmoglein internalization. 
Although this specificity may be defined 
by desmogleins themselves, recent 
results suggest that the spatiotemporal 
distribution of key factors in the keratino-
cyte adhesion-signaling network, such 
as p120 catenin binding to desmogleins, 
may contribute to signaling specificity. 
It should be emphasized, however, that 
not all signaling mechanisms should be 
regarded as primary events; rather, they 
can also be triggered later in the process 
of acantholysis and may not rely on des-
moglein endocytosis. They may impair 
desmoglein-mediated adhesion more 
indirectly, for example, by affecting the 
cytoskeletal anchorage of desmogleins 
or the cytoskeleton-mediated transport 
of desmosomal components to the sites 
of cell–cell contact. Evidence exists that 
cytoskeletal components beyond keratin 
become reorganized during acantho-
lysis but the relevance of these changes 
remains unclear. The question was raised 
whether the target of antibody binding 
or the hierarchy of signaling cascades 
matters for patients, because the modula-
tion of signaling pathways can ultimately 
prevent blistering.
Participants sought to explain how 
hyperproliferation, which is observed in 
pemphigus patients, can lead to acantho-
lysis. The participants agreed that there is 
no simple paradigm at present to explain 
how blocking proliferation leads to the 
restoration of adhesion. On the other 
hand, proliferation-associated signaling 
pathways may reflect a modified wound 
healing program that is also associated 
with decreased cell–cell adhesion, possi-
bly rendering keratinocytes more vulner-
able to pathogenic antibodies.
Finally, apoptosis and the recent apop-
tolysis model of pemphigus pathology 
was a topic of considerable discussion. 
The group agreed that apoptotic cell 
death is not a hallmark of pemphigus but 
that the apoptotic signaling machinery 
appears to be activated in response to the 
autoantibodies in pemphigus lesions. It 
was mentioned that some apoptotic sig-
naling effectors, including caspases, also 
participate in keratinocyte differentiation. 
Importantly, inhibition of caspase signal-
ing has been found to block acantholysis 
in response to pemphigus autoantibodies 
in some studies but not in others, leaving 
the relevance of these cell death-related 
mechanisms uncertain.
Finally, suggestions for the format 
of future workshops included the fol-
lowing: (i) a single workshop session 
after all podium talks to enable a more 
comprehensive discussion of the new 
findings presented at the meeting, (ii) 
encouraging young investigators to par-
ticipate in and lead the discussion, and 
(iii) focusing on a key topic area, such as 
the advantages and limitations of model 
systems for studying the mechanisms of 
pemphigus acantholysis.
Workshop ii: 
“Current knowledge  
in pemphigus treatment”
“Clinical Course, Activity, Prognosis, 
and Standard Therapeutic Options” 
(Chair: Luca Borradori, University of 
Berne, Switzerland). After two years of 
collaborative effort, a consensus state-
ment on the definitions of disease, end 
points, and therapeutic responses for 
pemphigus has been published (Murrell 
et al., 2008). Aiming at consistent report-
ing of outcomes, the pemphigus com-
munity highly recommends worldwide 
application of the statement.
Two new measurement instruments 
are currently being evaluated as reliable 
scoring systems to grade disease activity 
and standardize the practical manage-
ment of patients: the pemphigus disease 
area index and the autoimmune bullous 
skin disorder intensity score (Rosenbach 
et al., 2009). Preliminary findings 
indicate that the former is more repro-
ducible and correlates better with physi-
cians’ overall impression of a patient.
Prospective multicenter studies are 
urged in order to estimate the reliabil-
ity of these instruments in larger groups 
of patients (including those with severe 
disease) and their ability to capture 
variability in disease activity during 
the disease course. So far, the extent of 
disease, delayed responses to therapy 
and the presence of mucosal (including 
anogenital) involvement have emerged 
as negative predictive factors. Despite 
the development of highly sensitive and 
specific ELISAs, their practical useful-
ness for monitoring disease severity and 
their superiority in indirect immunofluo-
rescence microscopy, for example, have 
not been validated. Current evidence 
indicates that desmoglein 1 ELISA val-
ues correlate more closely with the 
course of disease than do desmoglein 
3 ELISA values (Abasq et al., 2009). 
Desmoglein 3 ELISA values remain high 
in a significant percentage of patients 
despite remission. Finally, no prospec-
tive studies have addressed the value of 
markers useful for either deciding when 
to stop therapy or predicting clinical 
relapses. Positive direct immunofluo-
rescence studies at cessation of therapy, 
a significant increase of desmoglein 1 
ELISA values, or very high desmoglein 3 
values may constitute fair predictors of 
further relapse.
Clinical interventions must be stan-
dardized, and the need for high-quality 
prospective clinical studies was under-
lined. Systemic glucocorticoid therapy 
has significantly improved the overall 
prognosis of affected patients; however, 
optimal glucocorticoid doses and the role 
of adjuvant immunosuppressive therapy 
(such as azathioprine, myco phenolate 
mofetil, and cyclophosphamide) remain 
unclear (Martin et al., 2009). A recent 
double-blind trial from Japan sug-
gests that patients relatively resistant 
to steroids benefit from intravenous 
Muller et al.
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immunoglobulins based on a novel, but 
somehow ill-defined end point: time to 
escape from protocol. The length of the 
period ending when a patient had been 
on the protocol without any additional 
treatment was significantly longer 
in patients who received a cycle of 
intravenous immunoglobulin compared 
with controls (Amagai et al., 2009).
Regarding the course and progno-
sis of pemphigus, a follow-up study of 
155 patients in Israel reported an over-
all mortality rate of 10%; none of the 
deaths could be directly associated with 
pemphigus. Patients who were young 
at diagnosis (<40 years), had mucosal 
involvement, or were of a distinct ethnic 
origin (such as Sephardic Jews) appear 
to have a poorer prognosis.
“Towards Novel Immunomodulatory 
Therapeutic Strategies” (Chair: Michael 
Hertl, Philipps University, Marburg, 
Germany). Based on the consensus that 
the immune pathogenesis of pemphi-
gus is primarily driven by IgG (or, rarely, 
IgA) autoantibodies against desmosom-
al adhesion molecules (Amagai et al., 
2006), their removal by immunoadsorp-
tion (IA) or intravenous immunoglobu-
lins (IVIG) should improve the overall 
disease course. Autoreactive B cells as 
the precursors of autoantibody-secreting 
plasma cells have become a major ther-
apeutic focus because treatment with 
B cell–depleting agents, such as ritux-
imab, has led to pronounced therapeu-
tic effects. It is not yet clear, however, 
whether autoreactive B cells fulfill addi-
tional functions, such as antigen presen-
tation for autoreactive T cells. Because 
autoreactive T cells are thought to be 
critical inducers and perpetuators of 
autoreactive B-cell responses, they may 
also represent a relevant therapeutic 
target. In pemphigus vulgaris, an imbal-
ance toward a pathogenic T-helper type 
2 phenotype is associated with a lack 
of autoreactive type 1 regulatory T cells 
(Hertl et al., 2006).
IA is considered a highly efficient 
procedure to rapidly deplete patho-
genic IgG autoantibodies in pemphi-
gus, and it is used as an adjuvant to 
the standard immunosuppressive treat-
ment. Specialized centers in Germany 
perform IA in refractory or extensive 
pemphigus with impressive therapeutic 
outcomes in single patients. A German 
multicenter prospective phase III IA trial 
will start in late 2010. Moreover, IA has 
been used successfully in combination 
with rituximab and/or immunoglobulins 
(Shimanovich et al., 2008; Pfütze et al., 
2009).
IVIG treatment has pleiotropic effects 
on various autoimmune responses. 
Specifically, IVIG blocks Fc receptors 
on inflammatory cells, induces autoan-
tibody catabolism through activation of 
the neonatal Fc receptor, and blocks B 
cell growth and survival factors such as 
B-cell-activating factor. Currently, IVIG 
is not approved for the treatment of pem-
phigus in most countries (Cines et al., 
2003). However, based on the findings 
of a multicenter, prospective, controlled 
trial, IVIG treatment of pemphigus was 
recently approved in Japan (Amagai et 
al., 2009). Further controlled clinical tri-
als are warranted to facilitate its wider 
use in dermatology.
Excellent results with rituximab were 
reported in a long-term follow-up of 
21 patients with severe types of pem-
phigus who received a single cycle of 
rituximab (mean follow-up: 58 months). 
Eighteen patients (81%) were in com-
plete remission or almost complete 
remission, three patients had persistent 
active disease, and two patients died 
(in one case, death was due to an unre-
lated cardiovascular cause). Among the 
patients in complete remission, seven 
(33%) and six (29%) were off therapy 
or on minimal therapy (less than 10 mg/
day prednisone), respectively. The 2-, 
3- and 5-year relapse rates were 33, 43, 
and 62%, respectively. Overall, the data 
seem to demonstrate a remarkable long-
term efficacy of rituximab and good tol-
erance to the drug. A multicenter study 
will soon be initiated in France to assess 
the efficacy of rituximab as a first-line 
and steroid-sparing agent.
Several B-cell-depleting antibodies 
that have been tried in human autoim-
mune diseases (Dörner and Burmester, 
2008; Nagel et al., 2009) target B-cell 
survival factors, such as B-cell-activating 
factor (belimumab) and may thus act 
synergistically with rituximab (Nagel 
et al., 2009). In addition to the deple-
tion of autoreactive B cells as plasma 
cell precursors, rituximab reduces the 
frequencies of desmoglein 3–specific 
T cells (Eming et al., 2008). Furthermore, 
rituximab also induces regulatory T cells 
as shown in systemic lupus erythema-
tosus (Sfikakis et al., 2007). Currently 
applied doses of rituximab are pre-
sumably higher than necessary; 1–2 g/
year should be sufficient. Elimination 
of autoreactive plasma cells using 
the proteasome inhibitor bortezomib 
may be another promising therapeutic 
approach.
Finally, based on findings in animal 
models of pemphigus, there is evidence 
that autoreactive B cells require T-cell 
help for autoantibody production (Aoki-
Ota et al., 2006). A recent Peptimmune 
phase I trial aimed at targeting autoreac-
tive T cells with a single immunodomi-
nant desmoglein 3–derived peptide 
(Anhalt et al., 2005) did not lead to con-
siderable clinical improvement. A major 
obstacle is potentially unexpected side 
effects of T-cell-based immune inter-
ventions, such as the de novo induction 
of immune-deviated T-cell responses, 
which have been identified in similar tri-
als in multiple sclerosis.
*The International Pemphigus Meeting on Advances 
in Pemphigus Research was held at the Hotel 
Allegro, Berne, Switzerland, 27–29 June 2009.
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